Committee for Medicinal Products for Human Use (CHMP) recommend addition of a new pharmaceutical form of buprenorphine/naloxone (Suboxone)

CHMP recommend addition of a sublingual film associated with four new strengths (2/0.5, 4/1, 8/2, and 16/4 mg) for either sublingual or buccal use. The new formulation adds additional safety features to prevent intravenous misuse.


European Medicines Agency